A seminal study published in Cell by researchers at Denali Therapeutics elucidated the development of this PTV:PGRN (DNL593) approach, shedding light on the pathogenesis of frontotemporal dementia (FTD) and lysosomal function in of PGRN deficiencies [93]. Here, GRN is linked to frontotemporal dementia.